Lallemand Health Solutions is pleased to announce that its documented probiotic strain Bifidobacterium animalis ssp. lactis LAFTI® B94 has been recognized by the Canadian Health Authorities for its gut health benefits in children, adolescents, and adults. In particular, for the reduction of constipation and bloating in children and adolescents with Irritable Bowel Syndrome (IBS), a growing concern in this sub-population group, as supported by a recent randomized clinical study (Ba?türk et al., 2016).
B. lactis LAFTI® B94 in children (above 4 years old) “Helps to relieve abdominal discomfort, such as bloating and constipation” and “Helps children and adolescents with bloating and constipation in irritable bowel syndrome (IBS)”. The strain is also authorized in infants from 2 months, with specific probiotic claims such as “Participates in a healthy microflora balance”. In adults, the probiotic is also recognized for its benefits as an adjunct to physician-supervised therapy in patients with Helicobacter pylori infections at higher daily doses.
Health Canada has also granted two new health claims for the probiotic strain Lactobacillus helveticus LAFTI® L10 dedicatd to active adults. Claims such as “Promotes gastrointestinal health in physically active adults” and “Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress” are now available for this unique probiotic strain. This confirms the value and benefits of L. helveticus LAFTI® L10 for active adults and sports nutrition, as backed-up by four clinical studies among which two focusing on athletes’ population.